|
KMID : 1130620210170010070
|
|
Journal of Clinical Neurology
2021 Volume.17 No. 1 p.70 ~ p.76
|
|
|
Platelet-Derived Growth Factor Is Associated with Progression of Symptomatic Intracranial Atherosclerotic Stenosis
|
|
Kim Kyeong-Joon
Jeong Sang-Wuk
Ryu Wi-Sun
Kim Dong-Eog
Saver Jeffrey L.
Kim Jong-S.
Kwon Sun-U.
|
|
|
Abstract
|
|
|
Background and Purpose: We aimed to determine the relationships of 33 biomarkers of inflammation, oxidation, and adipokines with the risk of progression of symptomatic intracranial atherosclerotic stenosis (ICAS).
Methods: Fifty-two of 409 patients who participated in the TOSS-2 (Trial of Cilostazol in Symptomatic Intracranial Stenosis-2) showed progression of symptomatic ICAS in magnetic resonance angiography at 7 months after an index stroke. We randomly selected 20 patients with progression as well as 40 age- and sex-matched control patients. We serially collected blood samples at baseline, 1 month, and 7 months after an index stroke. Multiplex analysis of biomarkers was then performed.
Results: Demographic features and risk factors such as hypertension, diabetes, and smoking history were comparable between the two groups. Univariate analyses revealed that the levels of platelet-derived growth factor (PDGF)-AA [median (interquartile range)=1.64 (0.76?4.57) vs. 0.77 (0.51?1.71) ng/mL], PDGF-AB/BB [10.31 (2.60?25.90) vs. 2.35 (0.74?6.70) ng/mL], and myeloperoxidase [10.5 (7.5?22.3) vs. 7.8 (5.5?12.2) ng/mL] at 7 months were higher in the progression group. In the multivariate analysis using logistic regression, the PDGF AB/BB level at 7 months was independently associated with the progression of ICAS (p=0.02).
Conclusions: The PDGF-AB/BB level is associated with the progression of ICAS, and so may play a significant role in the progression of human ICAS.
|
|
|
KEYWORD
|
|
|
platelet-derived growth factor, intracranial stenosis, ischemic stroke, magnetic resonance angiography
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
   
|